Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term Erasca (NASDAQ: ERAS) shareholders against certain of the company's officers and directors for alleged breaches of fiduciary duty, targeting holders continuously since before January 14, 2025. The notice recaps a previously filed securities complaint alleging that Erasca disclosed a letter from Revolution Medicines claiming ERAS-0015 infringed its patent, was connected to trade-secret misappropriation, and was improperly compared to RMC-6236; the complaint also cites preliminary Phase 1 data including a patient death and acknowledged cross-study comparisons were inherently limited.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.